The earnings call highlighted Daré Bioscience's strategic moves towards commercialization and revenue generation through an expanded business strategy and new product launches. However, financial challenges such as a working capital deficit and comprehensive loss, along with regulatory hurdles, present significant concerns.

Company Guidance -

Q3 2025

In the recent conference call, Daré Bioscience provided guidance on their strategic direction, highlighting a dual path strategy for product commercialization. They plan to bring four products to market, including their Sildenafil Cream and a monthly hormone therapy, targeting the estimated $4.5 billion hormone therapy market. They aim to record revenue in Q4 2025, capitalizing on a nimble business model that leverages both FDA approval and 503B compounding. Financially, Daré reported a Q1 2025 comprehensive loss of approximately $4.4 million, with general and administrative expenses reduced by 14% and R&D expenses by 31% compared to Q1 2024. They closed the quarter with $10.3 million in cash and a working capital deficit of $9.4 million. The company is actively pursuing strategic partnerships to enhance product access and plans to update stakeholders on these developments, alongside their ongoing pipeline progress, in the coming months.

Expanded Business Strategy

Daré Bioscience announced an expanded business strategy leveraging a dual path strategy to commercialize proprietary formulations via 503B compounding while continuing to seek FDA approval. This strategy aims to accelerate revenue generation and provide a path to profitability.

New Product Launches

Daré is planning to launch three more solutions for women, including two vaginal probiotics in 2025 and a proprietary monthly hormone therapy in 2026, targeting a $4.5 billion market.

Decrease in Operating Expenses

The company's general and administrative expenses decreased by 14%, and R&D expenses decreased by 31% compared to Q1 2024, reflecting cost management efforts.

Strategic Partnerships

Daré is seeking multiple strategic partnerships to provide women access to its evidence-based solutions across multiple channels, including collaborations with telehealth providers and online platforms.

Ovaprene Clinical Progress

The pivotal Phase 3 contraceptive efficacy study for Ovaprene is ongoing, with a Data Safety Monitoring Board interim assessment scheduled for July 2025.

Daré Bioscience (DARE) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

DARE Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	- / -	-0.55	―	―	―
Aug 07, 2025	2025 (Q2)	-0.58 / -	1.52	―	―	―
May 13, 2025	2025 (Q1)	- / -0.50	-0.84	40.48% (+0.34)	―
Mar 31, 2025	2024 (Q4)	-0.58 / -0.50	-0.84	40.48% (+0.34)	―
Nov 14, 2024	2024 (Q3)	-0.69 / -0.55	-1.094	49.73% (+0.54)	―
Aug 12, 2024	2024 (Q2)	-0.04 / 1.52	-1.2	226.67% (+2.72)	―
May 14, 2024	2024 (Q1)	-0.72 / -0.84	-1.08	22.22% (+0.24)	―
Mar 28, 2024	2023 (Q4)	-1.08 / -0.84	-2.28	63.16% (+1.44)	―
Nov 09, 2023	2023 (Q3)	-1.18 / -1.09	-0.96	-13.96% (-0.13)
Aug 10, 2023	2023 (Q2)	-1.18 / -1.20	0	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

DARE Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 13, 2025	$2.89	$2.89	0.00%
Mar 31, 2025	$2.89	$2.90	+0.35%
Nov 14, 2024	$3.56	$3.21	-9.83%
Aug 12, 2024	$3.50	$4.20	+20.00%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Daré Bioscience (DARE) report earnings?

Daré Bioscience (DARE) is schdueled to report earning on Aug 07, 2025, TBA (Confirmed).

What is Daré Bioscience (DARE) earnings time?

Daré Bioscience (DARE) earnings time is at Aug 07, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is DARE EPS forecast?

DARE EPS forecast for the fiscal quarter 2025 (Q2) is -0.58.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing